Treatment patterns and impact of glucocorticoids on health outcomes in generalized myasthenia gravis: a retrospective observational study based on the Medical Data Vision database in Japan
Most patients were treated with AChEi, GC, or NSIST monotherapy or combination therapies and received GCs exceeding 5 mg/day, which was associated with developing several GC-associated comorbidities in a dose-dependent manner. To achieve treatment goals, patients with gMG may benefit from additional treatment approaches to reduce GC usage.
Authors
- Daisuke Harada (ORCID: https://orcid.org/0000-0002-0075-5935)
- Koichi Tsuda (ORCID: https://orcid.org/0009-0004-4790-7301)
- C. Blein (ORCID: https://orcid.org/0000-0003-0900-8351)
- Hirofumi Teranishi
- Masanori Takahashi (ORCID: https://orcid.org/0000-0002-5513-5012)
- Mai Sato (ORCID: https://orcid.org/0000-0001-9620-3483)
- Anthony Nguyen
- Challa Yachendra
Institutions
- Zen Bio (United States) (US)
- Argenx (Belgium) (BE)
- The University of Osaka (JP)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-10-10
- DOI
- https://doi.org/10.3389/fneur.2025.1625457
- Citations
- 2
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Argenx